Clinical Trials Logo

Pancreatic Cancer Metastatic clinical trials

View clinical trials related to Pancreatic Cancer Metastatic.

Filter by:

NCT ID: NCT01652976 Completed - Clinical trials for Pancreatic Cancer Metastatic

Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma

FOLFOX-D
Start date: July 2012
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if the study drug, dasatinib, given in combination with 5-Fluorouracil, leucovorin and oxaliplatin (FOLFOX) will work against metastatic pancreatic cancer. Dasatinib is a Food and Drug Administration (FDA) approved drug for treating chronic myelogenous leukemia and acute lymphoblastic leukemia, however it is not currently approved for use in the treatment of pancreatic cancer.

NCT ID: NCT01600807 Withdrawn - Clinical trials for Pancreatic Cancer, Metastatic

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

OSI-906 is a new drug that may stop cancer cells from growing abnormally. This drug has been used in other research studies and information from those suggests that OSI-906 may help block cell receptors involved in tumor growth. Gemcitabine and erlotinib are used as standard treatment for pancreatic cancer. In this research study, the investigators are looking for the highest dose of OSI-906 that can be given safely in combination with gemcitabine and erlotinib. This dose will then be given together with gemcitabine and erlotinib to a further group of patients with pancreatic cancer.